JP2011516038A - バイオマーカー - Google Patents

バイオマーカー Download PDF

Info

Publication number
JP2011516038A
JP2011516038A JP2010550628A JP2010550628A JP2011516038A JP 2011516038 A JP2011516038 A JP 2011516038A JP 2010550628 A JP2010550628 A JP 2010550628A JP 2010550628 A JP2010550628 A JP 2010550628A JP 2011516038 A JP2011516038 A JP 2011516038A
Authority
JP
Japan
Prior art keywords
grn
level
acd
antibody
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010550628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516038A5 (enrdf_load_stackoverflow
Inventor
クリストファー ジョセフ ペンバートン，
アーサー マーク リチャーズ，
マイケル ゲイリー ニコールズ，
ティモシー グラント ヤンデル，
Original Assignee
オタゴ イノベーション リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オタゴ イノベーション リミテッド filed Critical オタゴ イノベーション リミテッド
Publication of JP2011516038A publication Critical patent/JP2011516038A/ja
Publication of JP2011516038A5 publication Critical patent/JP2011516038A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2010550628A 2008-03-12 2009-03-12 バイオマーカー Pending JP2011516038A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3576108P 2008-03-12 2008-03-12
US61/035,761 2008-03-12
PCT/NZ2009/000032 WO2009113880A1 (en) 2008-03-12 2009-03-12 Biomarkers

Publications (2)

Publication Number Publication Date
JP2011516038A true JP2011516038A (ja) 2011-05-26
JP2011516038A5 JP2011516038A5 (enrdf_load_stackoverflow) 2012-05-10

Family

ID=41065428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550628A Pending JP2011516038A (ja) 2008-03-12 2009-03-12 バイオマーカー

Country Status (7)

Country Link
US (1) US8507209B2 (enrdf_load_stackoverflow)
EP (1) EP2265642A4 (enrdf_load_stackoverflow)
JP (1) JP2011516038A (enrdf_load_stackoverflow)
CN (1) CN101977933A (enrdf_load_stackoverflow)
AU (1) AU2009224114B2 (enrdf_load_stackoverflow)
CA (1) CA2715921A1 (enrdf_load_stackoverflow)
WO (1) WO2009113880A1 (enrdf_load_stackoverflow)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US20100255518A1 (en) 2006-04-04 2010-10-07 Goix Philippe J Highly sensitive system and methods for analysis of troponin
DK2089722T3 (en) * 2006-09-07 2018-01-22 Otago Innovation Ltd BIOMARKET FOR EARLY DETECTION OF ACUTE HEART DISORDERS
JP5818440B2 (ja) * 2008-03-12 2015-11-18 オタゴ イノベーション リミテッド バイオマーカー
EP2440936A4 (en) 2009-06-08 2013-03-13 Singulex Inc GROUPS OF HIGHLY SENSITIVE BIOMARKERS
EP2524059A4 (en) 2010-01-13 2013-11-20 Caris Life Sciences Luxembourg Holdings DETECTION OF GASTROINTESTINAL DISEASES
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
KR101313184B1 (ko) * 2010-06-24 2013-09-30 한국표준과학연구원 질병 지표 검출 키트 및 질병 지표 검출 방법
EP3246335A3 (en) 2010-07-19 2017-12-27 Otago Innovation Limited Signal biomarkers
US20140147874A1 (en) * 2011-03-04 2014-05-29 The Johns Hopkins University Biomarkers of cardiac ischemia
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
EP2592422A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
WO2013141716A1 (en) * 2012-03-20 2013-09-26 Christopher Joseph Pemberton Biomarkers
KR102039522B1 (ko) * 2013-06-03 2019-11-26 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 근거리 무선 통신(ｎｆｃ)을 이용한 ｎｆｃ 태그의 기록방법 및 장치
IL283371B2 (en) 2018-11-30 2024-08-01 Caris Mpi Inc New generation molecular characterization
CA3163319A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005052593A1 (en) * 2003-10-29 2005-06-09 The University Of Leicester Detection

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
AU7568391A (en) 1990-05-07 1991-11-27 Immunomedics Inc. Improved method for radiolabeling monovalent antibody fragments
AU658374B2 (en) 1990-09-14 1995-04-13 Biosite Diagnostics Incorporated Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5221685A (en) 1991-02-01 1993-06-22 Ube Industries, Ltd. Thiazoline derivative, process for preparing the same and chemical for controlling noxious organisms containing the same
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
WO1992018868A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
EP1347493A3 (en) 1993-05-28 2005-11-23 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
ES2182836T3 (es) 1993-11-12 2003-03-16 Inverness Medical Switzerland Dispositivos de lectura para tiras de analisis.
DE69328180T2 (de) 1993-11-12 2000-09-21 Unilever N.V., Rotterdam Analysevorrichtung und deren Anwendung
US5647124A (en) 1994-04-25 1997-07-15 Texas Instruments Incorporated Method of attachment of a semiconductor slotted lead to a substrate
GB9419267D0 (en) 1994-09-23 1994-11-09 Unilever Plc Assay devices
US5792294A (en) 1995-11-16 1998-08-11 Otis Elevator Company Method of replacing sheave liner
US5719600A (en) 1995-12-12 1998-02-17 Hewlett-Packard Company Gradient calculation system and method
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
WO1999038194A1 (en) 1998-01-23 1999-07-29 Analytica Of Branford, Inc. Mass spectrometry from surfaces
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
JP2005513479A (ja) 2001-12-21 2005-05-12 センス プロテオミック リミテッド 質量分析用のプローブ
AUPS169202A0 (en) 2002-04-11 2002-05-16 Goetze, Jens Peter Neuropeptide assay
US6780645B2 (en) 2002-08-21 2004-08-24 Lifescan, Inc. Diagnostic kit with a memory storing test strip calibration codes and related methods
US7045366B2 (en) 2003-09-12 2006-05-16 Ciphergen Biosystems, Inc. Photocrosslinked hydrogel blend surface coatings
JP2006527190A (ja) 2003-04-17 2006-11-30 サイファージェン バイオシステムズ インコーポレイテッド ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法
US20050170368A1 (en) 2003-07-02 2005-08-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7176292B2 (en) * 2003-09-11 2007-02-13 Dialean, Ltd. Ghrelin variant protein
PL1773885T3 (pl) 2004-08-05 2010-09-30 Genentech Inc Humanizowani antagoniści anty c-met
EP1861416A1 (en) * 2005-03-09 2007-12-05 The Board of Trustees of Leland Stanford Junior University Obestatin and its uses
JP2006292623A (ja) 2005-04-13 2006-10-26 Univ Of Dundee 心不全における突然死のマーカー
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
GB0712670D0 (en) 2007-06-29 2007-08-08 King S College London Isolated peptides and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005052593A1 (en) * 2003-10-29 2005-06-09 The University Of Leicester Detection
US20050244904A1 (en) * 2003-10-29 2005-11-03 Leong Ng Diagnostics based on signal peptide detection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013063237; ＧＵＥＯＲＧＵＩＥＶ，　Ｍ．　ｅｔ　ａｌ．: 'Ａｃｃｅｓｓｉｏｎ　Ｎｏ．　Ａ２Ｔ３Ｘ２，　ＤＥＦＩＮＩＴＩＯＮ：　Ｇｈｒｅｌｉｎ　（Ｆｒａｇｍｅｎｔ）' Ｄａｔａｂａｓｅ　ＵｎｉＰｒｏｔ　［ｏｎｌｉｎｅ］ , 20080205 *
JPN6013063239; ＫＯＲＢＯＮＩＴＳ，　Ｍ．　ｅｔ　ａｌ．: 'Ｇｈｒｅｌｉｎ-ａ　ｈｏｒｍｏｎｅ　ｗｉｔｈ　ｍｕｌｔｉｐｌｅ　ｆｕｎｃｔｉｏｎｓ' Ｆｒｏｎｔｉｅｒｓ　ｉｎ　Ｎｅｕｒｏｅｎｄｏｃｒｉｎｏｌｏｇｙ Ｖｏｌ．２５，　Ｎｏ．１, 200404, ｐ．２７-６８ *
JPN6013063240; ＹＡＳＵＤＡ，　Ｓ．　ｅｔ　ａｌ．: 'Ｄｅｃｒｅａｓｅｄ　Ｓｅｒｕｍ　Ｇｈｒｅｌｉｎ　Ｌｅｖｅｌ　ｉｎ　Ｐａｔｉｅｎｔｓ　ｗｉｔｈ　Ａｃｕｔｅ　Ｍｙｏｃａｒｄｉａｌ　Ｉｎｆａｒｃｔｉｏｎ　：　Ｉｔｓ　Ａｓｓｏｃｉａｔｉｏｎ　ｗｉｔｈ　ｔｈ' Ｃｉｒｃｕｌａｔｉｏｎ　Ｊｏｕｒｎａｌ Ｖｏｌ．６８，　Ｎｏ．Ｓｕｐｐｌｅｍｅｎｔ＿Ｉ, 20040301, ｐ．１３４ *

Also Published As

Publication number Publication date
US8507209B2 (en) 2013-08-13
EP2265642A1 (en) 2010-12-29
CN101977933A (zh) 2011-02-16
US20110008808A1 (en) 2011-01-13
WO2009113880A1 (en) 2009-09-17
AU2009224114B2 (en) 2013-02-21
AU2009224114A1 (en) 2009-09-17
EP2265642A4 (en) 2012-05-02
CA2715921A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
US8507209B2 (en) Biomarkers
US8298772B2 (en) Methods of diagnosing acute cardiac disorders using BNP-SP
US10106575B2 (en) Biomarkers
US20110033874A1 (en) Biomarkers

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120220

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120312

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130509

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140609

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140924